Ernie Tremblay
Once singled out as the "most winning" stock-picker in the investment newsletter industry, Ernie Tremblay has more than 25 years of experience in following and analyzing the latest developments in health, medicine, and related technologies.
As a health editor and writer, he has contributed to more than 100 publications on topics like diabetes, Alzheimer's disease, arthritis, dermatology, and groundbreaking medical therapies, for top publishers such as Prentice Hall, Harper Collins, and others. Over the decades, Ernie has gained "insider" access to some of the world's top medical professionals, including Nobel-caliber doctors like Yale's Karel Liem, Columbia's George Gaylord Simpson, and Harvard's William S. Beck.
Ernie understands the FDA approval process, as well as the "hard science" behind new, experimental drugs and the market demand for them - and has a comprehensive grasp of the complex dynamics that determine whether a new drug will be a breakthrough winner, or just another casualty of the FDA approval process.
He puts that knowledge to work for members of his Biotech Insider Alert service, using a proprietary Three-Phase System that identifies the next "blockbuster" drugs and determines whether upcoming regulatory events will make a stock rocket skyward or plunge in the opposite direction . As a consulting editor for Money Map Press since 2012, Ernie's service has given readers opportunities to land substantial gains - including one bioscience stock that generated triple-digit gains four times in eight months.
Ernie'S LATEST HEADLINES
-
How to Find Tiny Stocks Packing Quadruple-Digit Profit Potential
Micro-cap and penny biotech stocks (those with a market cap at less than $300 million) have a reputation for being extremely speculative, volatile, and unpredictable.
But they can also deliver returns beyond your wildest expectations.
In fact, some of these companies have become legendary for minting millionaires, as they rocketed from bargain basement to stellar valuation. Others, of course, crashed and burned along the way.
In this investment niche, little is certain, but a little legwork can give you an edge when picking the winners from the also-rans.
In a moment, I'm going to show you two things I always look for when I'm researching these special stocks for my Biotech Insider Alert subscribers.
But first, I'll tell you what not to look for. That's going to save you a lot of time... - The One Thing You Must Know to Hit It Big in Biotech
- Bypass These Pitfalls to (Major) Profits in Bioscience
- How to Spot Biotech Shares with "Blockbuster" Potential
- This "Quick Doubler" Biotech Will Likely Disappoint
- How to Protect Your Biotech Profits from This Legal Limbo
- How to Make a (Consistent) Killing in Biotech Investing in 2016
- What Hillary's Pharma Plan Means for Biotech Investors
- Two Tactics for Bigger Biotech Investing Profits
- This Bioscience Company Has "Nearly Limitless" Income Potential